A breakthrough in healthcare: Cheaper medicines for chronic kidney disease and psoriasis are now available in Australia, thanks to the Pharmaceutical Benefits Scheme (PBS). This is a game-changer for those living with these conditions, offering hope and improved access to essential treatments.
For individuals battling chronic kidney disease, the PBS expansion includes Dapagliflozin (Forxiga®), which will benefit a larger population. Chronic kidney disease is a severe condition where the kidneys' filtering abilities deteriorate, leading to potential heart issues and kidney failure. This treatment aims to reduce kidney strain and slow down the disease's progression, providing a much-needed relief for patients.
The impact is significant, with an estimated 65,000 Australians expected to benefit annually. Without PBS, patients could be paying over $670 per prescription, an unaffordable burden for many.
In a similar move, Calcipotriol and betamethasone dipropionate (Wynzora®) are now listed for treating chronic stable plaque-type psoriasis vulgaris. Plaque psoriasis is a persistent skin condition causing itchy, scaly patches, often affecting one's daily life and confidence. Wynzora® and betamethasone work together to control skin cell overgrowth, reduce inflammation, and provide relief, improving the quality of life for psoriasis patients.
The numbers speak for themselves: over 141,000 patients accessed comparable treatments through PBS in 2024 alone. Without the subsidy, patients might be paying upwards of $65 per script. However, with PBS listing, eligible patients will pay a maximum of $25 per script, or just $7.70 with a concession card, making these life-changing medicines more accessible and affordable.
Since July 2022, the Australian Government has demonstrated its commitment by approving extra funding for 399 new and amended PBS listings. Minister Butler emphasizes, "These medicines are life-changing, offering hope and improved quality of life for those with distressing and deadly conditions. The Albanese Government is dedicated to ensuring Australians can access the medicines they need at an affordable price."
This initiative is a step towards ensuring equitable healthcare access, and we invite your thoughts and comments on this important development.
